Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO) specializing in the production of monoclonal antibodies and other biologics. The company operates primarily in the U.S., leveraging its state-of-the-art facilities in California to serve a diverse client base in the biotech sector, which includes both emerging and established pharmaceutical companies.
Business Overview
Avid generates revenue through contract manufacturing agreements, providing end-to-end services from cell line development to commercial production. The company has a competitive advantage due to its specialized expertise in mammalian cell culture processes and a flexible manufacturing model that allows for rapid scale-up to meet client demands.
New contract wins with biotech firms, particularly in monoclonal antibody production
Regulatory approvals for client products that utilize Avid's manufacturing services
Capacity expansions or upgrades that enhance production capabilities
Changes in industry demand for biologics manufacturing services
Risk Factors
Technological disruption in biologics manufacturing processes
Regulatory changes affecting the biotech industry
Emergence of new CDMO players with advanced technologies
Price competition from established CDMOs with lower cost structures
High debt levels relative to equity, increasing financial risk
Negative net margins indicating potential liquidity issues
Macro Sensitivity
moderate - The demand for biopharmaceuticals can be somewhat insulated from economic cycles, but significant downturns could impact client budgets for R&D.
Higher interest rates could increase Avid's financing costs and potentially dampen investment in biotech R&D, impacting demand for its services.
minimal - Avid's operations are not heavily reliant on credit, but its high debt-to-equity ratio indicates potential vulnerability to credit market conditions.
Profile
growth - Investors looking for exposure to the expanding biotech sector and contract manufacturing opportunities.
high - The stock has exhibited significant price fluctuations, reflecting its operational challenges and market sentiment.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
